Ivosidenib

In this video Aaron T. Gerds, MD, assistant professor in medicine at the Cleveland Clinic Taussig Cancer Institute, discusses a study presented at ASCO21 that looked at the combination of ivosidenib and venetoclax with and without azacitidine for acute myeloid leukemia.

Healio spoke with Jonathan M. Gerber, MD, chief of hematology-oncology and medical director of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, Eleanor Eustis Farrington Chair in Cancer Research and HemOnc Today Editorial Board member, about FDA approvals, the transition of newer agents into clinical practice and breakthroughs in therapy that he hopes to see in the future in this video series.

The FDA granted priority review to ivosidenib tablets for patients with previously treated IDH1-mutated cholangiocarcinoma, according to the agent’s manufacturer.

Ivosidenib modestly extended OS among patients with previously treated isocitrate dehydrogenase 1-mutated advanced cholangiocarcinoma, according to final results of the phase 3 ClarIDHy trial presented at Gastrointestinal Cancers Symposium.

Ivosidenib and venetoclax with or without azacitidine appeared safe and effective for the treatment of IDH1-positive myeloid malignancies, according to phase 1B/phase 2 study results presented during the ASCO20 Virtual Scientific Program.